Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 666 results for kidney or kidneys or renal

  1. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  2. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

  3. PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)

    NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .

  4. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  5. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  6. ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (HTG602)

    Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.

  7. Endopyelotomy for pelviureteric junction obstruction (HTG206)

    Evidence-based recommendations on endopyelotomy for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting small instruments either up through the urinary tract or down through the skin and into the kidney.

  8. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

    Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.

  9. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  10. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  11. Endoaortic balloon occlusion for cardiac surgery (HTG168)

    Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.

  12. Coordinating care:- What is the clinical and cost effectiveness of having keyworkers present in the context of renal replacement therapy (RRT)?

    clinical and cost effectiveness of having keyworkers present in the context of renal replacement therapy (RRT)? Any explanatory notes(if...

  13. Extracorporeal membrane oxygenation (ECMO) in postneonatal children (HTG17)

    Evidence-based recommendations on extracorporeal membrane oxygenation in postneonatal children. This involves connecting the child's internal circulation to an external blood pump and artificial lung.

  14. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

  15. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

    We have moved Diagnostics guidance 37 to become HealthTech guidance 530. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.